📊 AI Stock Rating — Summary

Apellis Pharmaceuticals reported revenue of $458.58 million for the quarter ending September 30, 2025, with a net income of $215.72 million, resulting in an EPS of $1.71. The company shows a strong net margin of 47% and free cash flow at $108.32 million. The company's balance sheet reveals a healthy position with assets totaling $1.06 billion, net of liabilities at $657.55 million, positioning its equity at $401.17 million. Net debt is negative, indicating more cash than debt, with cash reserves of $480.60 million. Apellis has refrained from debt repayment, stock repurchases, or dividends, focusing instead on strengthening its cash position. Analyst price targets suggest potential variability, with a consensus target of $33.71. P/E ratios and other valuation metrics were not provided for deeper valuation context.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue growth reflects strong momentum with a total of $458.58 million. The stability and drivers such as core product offerings are not detailed, suggesting moderate but stable growth.

Profitability — Score: 8/10

Solid profitability with a net margin of 47% and EPS of $1.71, suggesting efficient operations. Continued strength in net income contributes positively to this high score.

Cash Flow Quality — Score: 9/10

Strong free cash flow of $108.32 million, almost unchanged operating cash flows indicate high quality. No dividends or buybacks, but liquidity remains robust with significant cash reserves.

Leverage & Balance Sheet — Score: 9/10

Strong financial resilience with negative net debt indicating healthy cash reserves ($480.60 million) over liabilities. The company maintains a solid balance sheet with total equity of $401.17 million.

Shareholder Returns — Score: 5/10

No dividends or buybacks, thus shareholder returns based purely on capital appreciation. Relatively flat price performance over the considered periods keeps this score balanced.

Analyst Sentiment & Valuation — Score: 6/10

The analyst consensus price target of $33.71 suggests limited upside potential. Valuation details like P/E are not given, though perspectives indicate a cautiously optimistic outlook.

⚠ AI-generated — informational only, not financial advice.